Cagatay Arslan

Statistics

Publications

Citations

353

H-Index

Active since

2022

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Salford Royal NHS Foundation Trust

University Hospital Southampton NHS Foundation Trust

Centre Hospitalier de l’Université de Montréal

Keio University

Cagatay Arslan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in castration-resistant prostate cancer therapy, genitourinary cancer pharmacotherapy, and metastatic disease treatment.

Publications per year

2022–2023

Publications

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 288 citations · Full text

Medicine, Oncology, Pharmacology +16

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · Journal of Clinical Oncology · 2023 · 53 citations

Medicine, Oncology, Pharmacology +16

1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Fathy Saad, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · Annals of Oncology · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17

1–3 of 3